Encyclopedia of AIDS

Living Edition
| Editors: Thomas J. Hope, Douglas Richman, Mario Stevenson

Medication Adherence and HIV-Associated Neurocognitive Disorders (HAND)

  • David J. Moore
  • Jessica L. Montoya
  • Kaitlin B. Casaletto
  • J. Hampton Atkinson
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-9610-6_466-1


Among persons living with HIV infection, adherence to antiretroviral therapy (ART) and other prescribed medications is the critical factor associated with reductions in morbidity and mortality. As a result, HIV is often considered a chronic illness. There have been several advancements in ART medication development, formulation, and administration that have increased the ease of ART adherence as compared to the early years of the epidemic. Specifically, side effect profiles have improved medication tolerability, and there are newer combination medications that allow for most regimens to be between one to three pills per day. Along with the view that HIV has become a chronic illness, however, is the observation that the number of chronic comorbidities among those with HIV has grown. Thus, pill burden remains high among HIV-infected persons as compared to the general population, although many of the medications are for the treatment of HIV-related conditions...


Medication Adherence Prospective Memory Neurocognitive Impairment Medication Event Monitoring System Prospective Memory Task 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Blackstone K, Iudicello JE, Morgan EE, Weber E, Moore DJ, Ellis RJ, Grant I, Woods SP. Human immunodeficiency virus infection heightens concurrent risk of functional dependence in persons with long-term methamphetamine use. J Addict Med. 2013a;7(4):255–63.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Blackstone K, Woods SP, Weber E, Grant I, Moore DJ, the HNRC Group. Memory-based adherence strategies for antiretroviral medication management in HIV: an evaluation of clinical predictors, adherence behavior awareness, and effectiveness. AIDS Behav. 2013b;17(1):74–85.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Crum-Cianflone NF, Moore DJ, Letendre S, Roediger MP, Eberly L, Weintrob A, Ganesan A, Johnson E, Del Rosario R, Agan BK, Hale BR. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology. 2013;80(4):371–9.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Cysique LA, Brew BJ. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev. 2009;19(2):169–85.CrossRefPubMedGoogle Scholar
  5. Ettenhofer ML, Foley J, Castellon SA, Hinkin CH. Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS. Neurology. 2010;74(15):1217–22.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Finitsis DJ, Pellowski JA, Johnson BT. Text message intervention designs to promote adherence to antiretroviral therapy (ART): a meta-analysis of randomized controlled trials. PLoS One. 2014;9(2):e88166.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Genberg BL, Wilson IB, Bangsberg DR, Arnsten J, Goggin K, Remien RH, Simoni J, Gross R, Reynolds N, Rosen M, Liu H. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS. 2012;26(11):1415–23.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Heaton RK, Clifford DB, Franklin Jr DR, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087–96.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3–16.CrossRefPubMedGoogle Scholar
  10. Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Suppl 1):S19–25.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Letendre SL, Woods SP, Ellis RJ, Atkinson JH, Masliah E, van den Brande G, et al. Lithium improves HIV associated neurocognitive impairment. AIDS. 2006;20(14):1885–8.CrossRefPubMedGoogle Scholar
  12. Ortego C, Huedo-Medina TB, Llorca J, Sevilla L, Santos P, Rodríguez E, Warren MR, Vejo J. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011;15(7):1381–96.CrossRefPubMedGoogle Scholar
  13. Poquette AJ, Moore DJ, Gouaux B, Morgan EE, Grant I, Woods SP. Prospective memory and antiretroviral medication non-adherence in HIV: an analysis of ongoing task delay length using the memory for intentions screening test. J Int Neuropsychol Soc. 2013;19(2):155–61.CrossRefPubMedGoogle Scholar
  14. Winston A, Vera JH. Can antiretroviral therapy prevent HIV-associated cognitive disorders? Curr Opin HIV AIDS. 2014;9(1):11–6.CrossRefPubMedGoogle Scholar
  15. Woods SP, Dawson MS, Weber E, Gibson S, Grant I, Atkinson JH. Timing is everything: antiretroviral nonadherence is associated with impairment in time-based prospective memory. J Int Neuropsychol Soc. 2009;15(1):42–52.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  • David J. Moore
    • 1
  • Jessica L. Montoya
    • 2
  • Kaitlin B. Casaletto
    • 2
  • J. Hampton Atkinson
    • 3
  1. 1.Department of PsychiatryUniversity of California, San DiegoSan DiegoUSA
  2. 2.SDSU/UCSD Joint Doctoral Program in Clinical PsychologySan Diego State University/University of CaliforniaSan DiegoUSA
  3. 3.VA San Diego Healthcare System & Department of PsychiatryUniversity of California, San DiegoSan DiegoUSA